Video
Author(s):
George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).
George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).
The study aimed to understand the real-world effectiveness of antiviral agents
sofosbuvir (SOF), ledipasvir/sofosbuvir (LDV/ SOF) and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) by hepatitis C genotype and clinically relevant subgroup.
Using data from the Veterans Affairs healthcare system, 624 patients were evaluated regarding completion of treatments and sustained virologic response (SVR).
These results were both encouraging and interesting, says Ioannou.
Differences between SVR were seen between genotypes, with a SVR of 92.8 (95% CI 92.3-93.2) for genotype 1-infected patients with no significant difference between regimens; a SVR of 86.2% (95% CI 84.6-87.7) for genotype 2-infected patients treated with SOF and ribavirin; 74.8% (95% CI 72.2-77.3) for genotype 3-infected patients; and 89.6% (95% CI 82.8-93.9) for genotype 4-infected patients.
Just looking at genotype 1 patients, who had the highest success rates, the group that didn’t have liver cancer has an SVR was 94% and the SVR in the HCC group was 79%. This is a good rate for both groups, especially considering the outcomes for these patients before effective antiviral agents were available, says Ioannou. Among patients in this group that had HCC and then had a liver transplant, the success rate was almost as good as those who had never had liver cancer, at 94%.
This trend consisted across all the other genotypes, says Ioannou.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
2 Commerce Drive
Cranbury, NJ 08512